Regorafenib and Nivolumab Simultaneous Combination Therapy

NCT03406871 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Advanced and Metastatic Solid Tumor

Interventions

DRUG: Regorafenib
DRUG: Nivolumab

Sponsor

Kohei Shitara

Collaborators

[object Object]
[object Object]